- United States
- /
- Pharma
- /
- NasdaqCM:IXHL
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks
Reviewed by Simply Wall St
As major U.S. stock indexes experience slight declines, investors are keenly analyzing earnings reports and economic indicators to gauge the market's direction. In this context, penny stocks continue to capture attention for their potential value, despite being a term that may seem outdated. These smaller or newer companies can offer compelling investment opportunities when they exhibit strong financial foundations, and we will explore several such stocks that stand out in the current market landscape.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.7988 | $5.8M | ★★★★★★ |
| LexinFintech Holdings (NasdaqGS:LX) | $3.15 | $485.02M | ★★★★★★ |
| Flexible Solutions International (NYSEAM:FSI) | $3.47 | $45.02M | ★★★★★★ |
| RLX Technology (NYSE:RLX) | $1.62 | $2.1B | ★★★★★★ |
| ARC Document Solutions (NYSE:ARC) | $3.42 | $147.91M | ★★★★★★ |
| Imperial Petroleum (NasdaqCM:IMPP) | $3.77 | $114.05M | ★★★★★★ |
| Permianville Royalty Trust (NYSE:PVL) | $1.57 | $52.63M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
| PHX Minerals (NYSE:PHX) | $3.63 | $137.99M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $1.09 | $96.23M | ★★★★★☆ |
Click here to see the full list of 752 stocks from our US Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Incannex Healthcare (NasdaqGM:IXHL)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Incannex Healthcare Inc. is a clinical stage pharmaceutical development company focused on medicinal cannabinoid and psychedelic products, with a market cap of $41.64 million.
Operations: The company's revenue is derived from its segment focused on psychedelic medicine and therapies for the treatment of mental health disorders, generating $0.012 million.
Market Cap: $41.64M
Incannex Healthcare Inc., a clinical-stage pharmaceutical company, remains pre-revenue with sales of just US$0.012 million and a net loss of US$18.46 million for the year ending June 2024. The company's strategic focus on psychedelic medicine is underscored by recent FDA approval for its Phase 2 clinical trial investigating psilocybin for anxiety disorders. Additionally, Incannex secured A$6.9 million in debt financing aligned with Australia's R&D Tax Incentive program, providing non-dilutive funding essential for ongoing research without impacting shareholder equity. Despite high volatility and an inexperienced management team, these developments highlight potential growth avenues in innovative therapies.
- Dive into the specifics of Incannex Healthcare here with our thorough balance sheet health report.
- Learn about Incannex Healthcare's historical performance here.
Performant Financial (NasdaqGS:PFMT)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Performant Financial Corporation offers technology-enabled audit, recovery, and analytics services in the United States and has a market cap of approximately $294.86 million.
Operations: The company's revenue is derived from its Business Services segment, totaling $119.23 million.
Market Cap: $294.86M
Performant Financial Corporation, with a market cap of approximately US$294.86 million, has shown revenue growth in its Business Services segment, reporting US$29.36 million for Q2 2024. Despite being unprofitable, the company has reduced losses over five years and maintains a strong cash position exceeding its total debt. Revenue is forecasted to grow by 13.01% annually, though profitability remains elusive in the near term. Recent shelf registration filings totaling US$143.56 million suggest potential capital raising activities to support operations or expansion plans, while analyst consensus indicates significant upside potential in stock price appreciation despite current undervaluation concerns.
- Jump into the full analysis health report here for a deeper understanding of Performant Financial.
- Learn about Performant Financial's future growth trajectory here.
FREYR Battery (NYSE:FREY)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: FREYR Battery, Inc. offers battery solutions across the United States, Norway, and internationally with a market cap of approximately $147.51 million.
Operations: FREYR Battery, Inc. does not have any reported revenue segments at this time.
Market Cap: $147.51M
FREYR Battery, Inc., with a market cap of approximately US$147.51 million, is a pre-revenue company in the battery solutions sector. The firm has experienced significant volatility in its share price and remains unprofitable with increasing losses over the past five years. Despite this, it maintains a strong cash position, with short-term assets of US$234.4 million exceeding both short-term and long-term liabilities. Recent executive changes include appointing Michael Brose as COO to bolster operations amid strategic shifts following re-domiciliation to the U.S., while shelf registration filings indicate potential capital raising activities for future growth initiatives.
- Take a closer look at FREYR Battery's potential here in our financial health report.
- Gain insights into FREYR Battery's outlook and expected performance with our report on the company's earnings estimates.
Make It Happen
- Get an in-depth perspective on all 752 US Penny Stocks by using our screener here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Jump on the AI train with fast growing tech companies forging a new era of innovation.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:IXHL
Incannex Healthcare
A clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia.
Flawless balance sheet with slight risk.
Market Insights
Weekly Picks

The "Sleeping Giant" Stumbles, Then Wakes Up
Swiped Left by Wall Street: The BMBL Rebound Trade

Duolingo (DUOL): Why A 20% Drop Might Be The Entry Point We've Been Waiting For

Ferrari's Intrinsic and Historical Valuation
Recently Updated Narratives
Booking Holdings: Why Ground-Level Travel Trends Still Favor the Platform Giants

Looking to be second time lucky with a game-changing new product

Adobe - A Fundamental and Historical Valuation
Popular Narratives

The "Sleeping Giant" Stumbles, Then Wakes Up
